ENDRA Life Sciences (NDRA) Change in Receivables (2017 - 2018)
ENDRA Life Sciences' (NDRA) quarterly Change in Receivables came in at -$12275.0 in Q4 2018, down 279.2% year-over-year from $6850.0 in Q4 2017, and down 2530.69% quarter-over-quarter from $505.0 in Q3 2018.
Powered by 
Analysis
ENDRA Life Sciences (NDRA) Change in Receivables (2017 - 2018) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Change in Receivables for 2 consecutive years, with -$12275.0 the latest figure, recorded in Q4 2018.
- On a quarterly basis, Change in Receivables fell 279.2% year-over-year to -$12275.0 in Q4 2018; TTM through Sep 2019 was -$12275.0, a 200.0% decrease from a year earlier, with the FY2018 full-year figure at -$6850.0, down 200.0% from the prior year.
- Change in Receivables was -$12275.0 for Q4 2018 at ENDRA Life Sciences, down from $505.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $6850.0 in Q4 2017 and troughed at -$12275.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 28.97 Bn | 27.09 Bn | 2.18 Bn | 79.00 Mn |
| 2 | Lantheus Holdings | 6.56 Bn | 5.97 Bn | 241.86 Mn | -3.28 Mn |
| 3 | Heartflow | 4.40 Bn | 4.03 Bn | 53.19 Mn | - |
| 4 | Neogen | 2.83 Bn | 2.64 Bn | 107.80 Mn | 9.80 Mn |
| 5 | Butterfly Network | 1.88 Bn | 1.75 Bn | 23.29 Mn | 10.05 Mn |
| 6 | Ceribell | 931.50 Mn | 802.24 Mn | 25.94 Mn | 283,000.00 |
| 7 | Varex Imaging | 779.32 Mn | 694.02 Mn | 76.70 Mn | -3.20 Mn |
| 8 | Anbio Biotechnology | 755.43 Mn | 743.53 Mn | - | - |
| 9 | QuidelOrtho | 725.35 Mn | 601.95 Mn | - | -8.90 Mn |
| 10 | ENDRA Life Sciences | 8.25 Mn | 2.71 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | -12,275.00 |
| Sep 30, 2018 | 505.00 |
| Mar 31, 2018 | 4,920.00 |
| Dec 31, 2017 | 6,850.00 |